Cytokinetics Inc
CYTK
查看详细走势图
62.340USD
+2.100+3.49%
收盘 02/06, 16:00（美东）报价延迟15分钟
7.61B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+3.49%
5天
-1.35%
1月
-4.71%
6月
+76.85%
今年开始到现在
-1.89%
1年
+45.79%
查看详细走势图
TradingKey Cytokinetics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Cytokinetics Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名53/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价89.82。中期看，股价处于平稳状态。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cytokinetics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Cytokinetics Inc亮点
亮点风险
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
业绩增长期
公司处于发展阶段，最新年度总收入18.47M美元
利润高增长
公司净利润处于行业前列，最新年度总收入18.47M美元
估值合理
公司最新PE估值-9.88，处于3年历史合理位
机构加仓
最新机构持股145.87M股，环比增加0.10%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值627.00
活跃度增加
近期活跃度增加，过去20天平均换手率0.04
分析师目标
根据
20
位分析师
买入
评级
89.824
目标均价
+41.41%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cytokinetics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cytokinetics Inc简介
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
公司代码CYTK
公司Cytokinetics Inc
CEOBlum (Robert I)
网址https://cytokinetics.com/
相关品种
